Literature DB >> 20160249

Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings.

Ingrid Eshun-Wilson1, Fiona Havers, Jean B Nachega, Hans W Prozesky, Jantjie J Taljaard, Michele D Zeier, Mark Cotton, Gary Simon, Patrick Soentjens.   

Abstract

OBJECTIVE: Standardized case definitions have recently been proposed by the International Network for the Study of HIV-associated immune reconstitution inflammatory syndrome (INSHI; [IRIS]) for use in resource-limited settings. We evaluated paradoxical tuberculosis (TB)-associated IRIS in a large cohort from a TB endemic setting with the use of these case definitions.
DESIGN: A retrospective cohort study.
METHOD: We reviewed records from 1250 South African patients who initiated antiretroviral therapy (ART) over a 5-year period.
RESULTS: A total of 333 (27%) of the patients in the cohort had prevalent TB at the initiation of ART. Of 54 possible paradoxical TB-associated IRIS cases, 35 fulfilled the INSHI case definitions (11% of TB cases).
CONCLUSIONS: INSHI-standardized case definitions were used successfully in identifying paradoxical TB-associated IRIS in this cohort and resulted in a similar proportion of TB IRIS cases (11%) as that reported in previous studies from resource-limited settings (8%-13%). This case definition should be evaluated prospectively.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160249      PMCID: PMC3068527          DOI: 10.1177/1545109710361537

Source DB:  PubMed          Journal:  J Int Assoc Physicians AIDS Care (Chic)        ISSN: 1545-1097


  14 in total

1.  Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2007-01-30       Impact factor: 4.177

2.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS.

Authors:  M Narita; D Ashkin; E S Hollender; A E Pitchenik
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

3.  Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control.

Authors:  Stephen D Lawn; Landon Myer; Linda-Gail Bekker; Robin Wood
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

4.  Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

Authors:  Guillaume Breton; Xavier Duval; Candice Estellat; Xavier Poaletti; Daniel Bonnet; David Mvondo Mvondo; Pascale Longuet; Catherine Leport; Jean-Louis Vildé
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

5.  Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India.

Authors:  N Kumarasamy; Sreekanth Chaguturu; Kenneth H Mayer; Suniti Solomon; H Tokugha Yepthomi; Pachamuthu Balakrishnan; Timothy P Flanigan
Journal:  J Acquir Immune Defic Syndr       Date:  2004-12-15       Impact factor: 3.731

6.  Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy.

Authors:  Samuel A Shelburne; Fehmida Visnegarwala; Jorge Darcourt; Edward A Graviss; Thomas P Giordano; A Clinton White; Richard J Hamill
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

7.  Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection.

Authors:  R A M Breen; C J Smith; H Bettinson; S Dart; B Bannister; M A Johnson; M C I Lipman
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

8.  Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis.

Authors:  W Burman; S Weis; A Vernon; A Khan; D Benator; B Jones; C Silva; B King; C LaHart; B Mangura; M Weiner; W El-Sadr
Journal:  Int J Tuberc Lung Dis       Date:  2007-12       Impact factor: 2.373

9.  Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Authors:  Christos Michailidis; Anton L Pozniak; Sundhiya Mandalia; Sheena Basnayake; Mark R Nelson; Brian G Gazzard
Journal:  Antivir Ther       Date:  2005

10.  Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.

Authors:  Graeme Meintjes; Stephen D Lawn; Fabio Scano; Gary Maartens; Martyn A French; William Worodria; Julian H Elliott; David Murdoch; Robert J Wilkinson; Catherine Seyler; Laurence John; Maarten Schim van der Loeff; Peter Reiss; Lut Lynen; Edward N Janoff; Charles Gilks; Robert Colebunders
Journal:  Lancet Infect Dis       Date:  2008-08       Impact factor: 25.071

View more
  13 in total

1.  Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.

Authors:  Francesca Conradie; Andrea S Foulkes; Prudence Ive; Xiangfan Yin; Katerina Roussos; Deborah K Glencross; Denise Lawrie; Wendy Stevens; Luis J Montaner; Ian Sanne; Livio Azzoni
Journal:  J Acquir Immune Defic Syndr       Date:  2011-11-01       Impact factor: 3.731

2.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.

Authors:  Olivia Keiser; Benjamin H Chi; Thomas Gsponer; Andrew Boulle; Catherine Orrell; Sam Phiri; Nicola Maxwell; Mhairi Maskew; Hans Prozesky; Matthew P Fox; Andrew Westfall; Matthias Egger
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

3.  Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.

Authors:  Annelies Van Rie; Shobna Sawry; Ruth Link-Gelles; Shabir Madhi; Lee Fairlie; Charl Verwey; Nasreen Mahomed; David Murdoch; Harry Moultrie
Journal:  Pediatr Pulmonol       Date:  2015-06-14

4.  Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence.

Authors:  Jean B Nachega; Chelsea Morroni; Richard E Chaisson; Rene Goliath; Anne Efron; Malathi Ram; Gary Maartens
Journal:  Patient Prefer Adherence       Date:  2012-12-12       Impact factor: 2.711

5.  HIV-Associated Tuberculosis.

Authors:  Kogieleum Naidoo; Kasavan Naidoo; Nesri Padayatchi; Quarraisha Abdool Karim
Journal:  Clin Dev Immunol       Date:  2010-09-13

6.  Clinical characteristics of tuberculosis-associated immune reconstitution inflammatory syndrome in North Indian population of HIV/AIDS patients receiving HAART.

Authors:  Suman Karmakar; Surendra K Sharma; Richa Vashishtha; Abhishek Sharma; Sanjay Ranjan; Deepak Gupta; Vishnubhatla Sreenivas; Sanjeev Sinha; Ashutosh Biswas; Vinay Gulati
Journal:  Clin Dev Immunol       Date:  2010-12-01

7.  Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis.

Authors:  Rebecca Tadokera; Katalin A Wilkinson; Graeme A Meintjes; Keira H Skolimowska; Kerryn Matthews; Ronnett Seldon; Molebogeng X Rangaka; Gary Maartens; Robert J Wilkinson
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

8.  Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling study.

Authors:  Janne Estill; Matthias Egger; Leigh F Johnson; Thomas Gsponer; Gilles Wandeler; Mary-Ann Davies; Andrew Boulle; Robin Wood; Daniela Garone; Jeffrey S A Stringer; Timothy B Hallett; Olivia Keiser
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

9.  Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome.

Authors:  Rebecca Tadokera; Graeme A Meintjes; Katalin A Wilkinson; Keira H Skolimowska; Naomi Walker; Jon S Friedland; Gary Maartens; Paul T G Elkington; Robert J Wilkinson
Journal:  Eur J Immunol       Date:  2013-10-30       Impact factor: 5.532

10.  Incidence of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and impact on patient outcome.

Authors:  Maryline Bonnet; Elisabeth Baudin; Ilesh V Jani; Elizabete Nunes; François Verhoustraten; Alexandra Calmy; Rui Bastos; Nilesh B Bhatt; Christophe Michon
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.